Citi Pharma Limited announced that its wholly owned subsidiary, Citi Veterinary Limited, has officially commenced its trading operations. The company is initially launching 32 veterinary products, including vaccines, with Letters of Credit (LCs) already established for 8 products to ensure timely supply availability.
The pharma giant shared this development through a notification to the Pakistan Stock Exchange (PSX) on Friday.
“Citi Pharma Limited is pleased to announce that its wholly owned subsidiary, Citi Veterinary Limited, has formally commenced trading operations,” read the notice.
For the fiscal year 2025-26, Citi Veterinary Limited expects a turnover of approximately PKR 1,500 million, with a projected gross profit margin of 13%.
The company said that its strong partnerships with supply chain partners in China, where dedicated veterinary divisions have been set up, are expected to play a key role in ensuring a reliable and consistent supply in Pakistan’s veterinary healthcare market.
Looking ahead, Citi Veterinary Limited has set an ambitious target of achieving a turnover of PKR 10 billion within the next three years. On the production front, the company has already submitted a layout plan to the Drug Regulatory Authority of Pakistan (DRAP), with an inspection expected in December 2025.
The company has also established LCs for importing additional machinery and acquired locally manufactured machinery to set up its production facilities. Trial production is expected to begin by the end of Q4 of FY 2025-26, with commercial production set to start in FY 2026-27.
In a major move, Citi Veterinary Limited plans to establish Pakistan’s first dedicated veterinary Active Pharmaceutical Ingredient (API) plant during FY 2026-27. This would mark a pioneering step in the country’s veterinary pharmaceutical industry. Once in-house production begins, the company anticipates a significant increase in its gross profit margin, which is expected to rise to approximately 25%, enhancing operational efficiency and value addition.
Citi Veterinary Limited expressed confidence that these developments will contribute to Pakistan’s veterinary pharmaceutical industry, while further strengthening Citi Pharma Limited’s diversified portfolio.
